Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) campaigners and (b) stakeholders on treatment for (i) lobular breast cancer and (ii) other rare cancers.

Improving outcomes and experiences of cancer treatment, including lobular breast cancer and other rare cancers, is a priority for the Government. Engagement with campaigners and partners is vital to achieving this.

My rt. Hon. Friend, the Secretary of State for Health and Social Care, accompanied by my hon. Friend, the Minister of State for Health, met with representatives of the Lobular Moonshot Project on 14 July 2025 to discuss their work. Following this meeting, the Chief Scientific Adviser and officials from the Department and the Medical Research Council (MRC) met again with the Lobular Moonshot Project to provide advice on existing funding options. Both the MRC and the National Institute for Health and Care Research have committed to continuing to work with the Lobular Moonshot Campaign team to support the development of fundable research proposals in this area and help drive our collective ambition to increase understanding and effective management of this disease.

In April 2025, I attended an event with Cancer Research UK, Macmillan, and Cancer52. The was followed by a roundtable in May 2025, in which I met with Cancer52 members, representing a wide range of cancer types, to discuss how the National Cancer Plan can prioritise rare cancers, to make a meaningful difference to how patients experience cancer treatment, and to bring cancer survivability back up to the standards of the best in the world. I have also met with brain cancer campaigners and All-Party Parliamentary Group members on several occasions since taking up post.

The National Cancer Plan will include more details about improving treatments for all tumour types, including lobular breast cancer. The Department continues to engage with a wide range of cancer partners on the Plan, including charities and patient representative bodies.